Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has presented important data from its ATH434-201 Phase 2 clinical trial at the 150th Annual Meeting of the American Neurological Association (ANA) in Baltimore, USA. The trial focused on Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. These results mark a significant milestone for Alterity as it moves closer to providing the first disease-modifying therapy for MSA.